Status:

TERMINATED

Efficacy of Clean Intermittent Catheterization (CIC) in Multiple Sclerosis (MS) Patients With Bladder Dysfunction

Lead Sponsor:

Wellspect HealthCare

Conditions:

Bladder Dysfunction

Multiple Sclerosis

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The aims of this prospective, randomized study are: * To assess the effect of clean intermittent catheterization (CIC) * To investigate if MS patients will have symptom reduction (urgency, frequency,...

Eligibility Criteria

Inclusion

  • Provision of informed consent
  • Male and female patients aged 18 years and over
  • MS patients that are already currently treated or eligible for treatment with anticholinergic drugs
  • Patient with previously confirmed multiple sclerosis according to McDonald Criteria and level of disability less than 6.5 on the Kutzke scale and have been stable for 6 months
  • The patient has all or any bladder symptoms; urgency, frequency, incontinence, nocturia, PVR
  • The patient has Frequency symptoms \> 8 voiding per 24 h
  • The patient has PVR \> 50 ml, measured at two repetitive bladder scan measurements during the screening phase as well as the randomization visit
  • Adequate mobility to lower limbs, sufficient hand function and ability to practice CIC at least three times daily

Exclusion

  • Pregnancy
  • Ongoing symptomatic Urinary Tract Infection (UTI) as judged by investigator
  • Involvement in the planning and conduct of the study (applies to both Astra Tech staff or staff at the study site)
  • The patient practices CIC prior the study
  • The patient has undergone a sphincterectomy
  • Progressive "Relapsing- remitting MS" as judged by the investigator
  • Severe non-compliance to protocol as judged by the investigator and/or Astra Tech
  • The patient is participating in other study that might have an impact on the outcome of this, as judged by investigator
  • PVR \> 250 ml, measured at two repetitive bladder scan measurements during the screening phase as well as the randomization visit and or if Bladder Voiding Efficiency (BVE) at visit 2 (randomization) is 50% or less than visit 1 (screening)

Key Trial Info

Start Date :

December 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2012

Estimated Enrollment :

24 Patients enrolled

Trial Details

Trial ID

NCT00913510

Start Date

December 1 2009

End Date

May 1 2012

Last Update

November 11 2021

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Centre Hospitalier Universitaire de Liège Ourthe Ambléve

Esneux, Belgium, 4130

2

UZ Gasthuisberg

Leuven, Belgium, 3000

3

St. Hedwig Hospital, Department of Urology

Berlin, Germany, 10115

4

UMC ST Radboud Nijmegen, Department of Urology

Nijmegen, Netherlands, 6500 HB